Macromoltek logo

Macromoltek

Computational antibody design

Winter 2018Healthcare / Healthcare -> Drug Discovery and DeliveryAustin, TX, USA14 employees
AI-powered Drug Discovery
Deep Learning
Therapeutics

About

Macromoltek: Revolutionizing antibody design. Description: Macromoltek, a computational de novo drug design company, rapidly produces accurate and credible antibody designs. We have built a proprietary platform that enables design against difficult targets inaccessible by traditional methods and have are already designing antibodies for large biopharmas and smaller biotechs.

Build your own investing agent

GPAgent keeps YC listings public and neutral. Fund-specific scoring, notes, and workflow state live in each customer workspace.

Join the GPAgent waitlist

Founders (2)

Monica Berrondo
Founder/CEO
Susana Kaufmann
Founder/CTO

Details

Status
Active
Stage
Early
Team Size
14
Regions
United States of America, America / Canada